Blog
RSS FeedPosted by Michael Wonder on 11 Dec 2023
ICER identifies most significant 2022 US drug price hikes unsupported by new clinical evidence
11 December 2023 - Of 10 high expenditure drugs that had substantial 2022 net price increases, eight were not supported by ...
Posted by Michael Wonder on 19 Apr 2023
ICER publishes white paper evaluating best practices and potential reforms for white bagging, brown bagging, and site of service policies that seek to address high markup in drug prices
19 April 2023 - White bagging, brown bagging, and site of service policies developed by payers can reduce significant markup costs ...
Posted by Michael Wonder on 12 Mar 2023
The value of medical innovation versus industry rewards
10 March 2023 - This article provides systematic evidence on the share of the value of health generated by drugs and ...
Posted by Michael Wonder on 07 May 2021
Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it
7 May 2021 - A key element in the long-simmering debate on reining in drug prices in the United States ...
Posted by Michael Wonder on 12 Jan 2021
ICER identifies most significant 2019 US drug price hikes — even after rebates — that were not supported by new clinical evidence
12 January 2021 - Out of 10 identified drugs that had substantial 2019 price increases on top of already high current ...
Posted by Michael Wonder on 08 Jun 2020
Fate of pharma’s reputation lies in Gilead’s hands on pricing of COVID-19 drug remdesivir
8 June 2020 - Few remember the time when the pharmaceutical industry was the world’s most admired. ...
Posted by Michael Wonder on 03 Dec 2019
Does the Institute for Clinical and Economic Review revise its findings in response to industry comments?
2 December 2019 - The ICER has gained prominence through its work conducting health technology assessments of pharmaceuticals in the United ...
Posted by Michael Wonder on 10 Sep 2019
ICER's blasted pharma pricing for years, but now drug makers are 'rolling up their sleeves' to cooperate
10 September 2019 - Sanofi and Regeneron's next-gen cholesterol drug Praluent never lived up to early expectations, and its price ...
Posted by Michael Wonder on 29 Dec 2017
ICER’s guideline on the acceptance and use of “in-confidence” data from manufacturers of pharmaceuticals, devices, and other health care interventions
22 December 2017 - ICER takes its obligations to transparency and fairness seriously. ...